Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bristol-Myers slates U.S. biologics
March 13, 2006
| A version of this story appeared in
Volume 84, Issue 11
Bristol-Myers Squibb plans to spend $660 million on a large-scale, multiproduct, bulk biologics manufacturing facility in the U.S. A spokesman says the firm has narrowed site selection to locations in Massachusetts, New York, North Carolina, and Rhode Island and that the firm will pick a site by midyear. BMS recently launched Orencia, its first internally developed biologic drug, for the treatment of rheumatoid arthritis. The company now manufactures Orencia at a plant in Syracuse, N.Y., that is not large enough for commercial-scale production.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter